These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8695922

  • 41. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
    Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC.
    Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
    [Abstract] [Full Text] [Related]

  • 42. Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation.
    Furuya Y, Ohta S, Ito H.
    Anticancer Res; 1997 Mar; 17(3C):2089-93. PubMed ID: 9216669
    [Abstract] [Full Text] [Related]

  • 43. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S, Benchokroun Y, Larsen AK.
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [Abstract] [Full Text] [Related]

  • 44. DNA topoisomerase inhibitors.
    Capranico G, Giaccone G, Zunino F, Garattini S, D'Incalci M.
    Cancer Chemother Biol Response Modif; 1994 May; 15():67-86. PubMed ID: 7779607
    [No Abstract] [Full Text] [Related]

  • 45. Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.
    Plo I, Hernandez H, Kohlhagen G, Lautier D, Pommier Y, Laurent G.
    J Biol Chem; 2002 Aug 30; 277(35):31407-15. PubMed ID: 12105221
    [Abstract] [Full Text] [Related]

  • 46. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
    Khélifa T, Beck WT.
    Mol Pharmacol; 1999 Mar 30; 55(3):548-56. PubMed ID: 10051540
    [Abstract] [Full Text] [Related]

  • 47. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
    Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS, Pommier Y.
    EMBO J; 1999 Mar 01; 18(5):1397-406. PubMed ID: 10064605
    [Abstract] [Full Text] [Related]

  • 48. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
    Kaufmann SH.
    Cancer Res; 1989 Nov 01; 49(21):5870-8. PubMed ID: 2790800
    [Abstract] [Full Text] [Related]

  • 49. Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells.
    Lumelsky NL, Schwartz BS.
    Cancer Res; 1996 Sep 01; 56(17):3909-14. PubMed ID: 8752157
    [Abstract] [Full Text] [Related]

  • 50. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M, Harada T, Tanaka T, Kuwano M.
    Nihon Rinsho; 1997 May 01; 55(5):1096-102. PubMed ID: 9155159
    [Abstract] [Full Text] [Related]

  • 51. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T, Takemura H, Yamashita T, Ishisaka T, Inai K, Imamura S, Urasaki Y, Ueda T.
    Anticancer Res; 1999 May 01; 19(6B):5111-5. PubMed ID: 10697518
    [Abstract] [Full Text] [Related]

  • 52. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
    Meinhardt G, Roth J, Totok G.
    Eur J Cell Biol; 2000 Nov 01; 79(11):824-33. PubMed ID: 11139146
    [Abstract] [Full Text] [Related]

  • 53. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C, Covey JM, Kerrigan D, Pommier Y.
    Cancer Res; 1989 Nov 15; 49(22):6365-8. PubMed ID: 2553254
    [Abstract] [Full Text] [Related]

  • 54. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
    Ritke MK, Rusnak JM, Lazo JS, Allan WP, Dive C, Heer S, Yalowich JC.
    Mol Pharmacol; 1994 Oct 15; 46(4):605-11. PubMed ID: 7969039
    [Abstract] [Full Text] [Related]

  • 55. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H, Latta M, Künstle G, Dhakshinamoorthy S, Ng PY, Porter AG, Wendel A.
    Hepatology; 2004 May 15; 39(5):1311-20. PubMed ID: 15122760
    [Abstract] [Full Text] [Related]

  • 56. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T.
    Nihon Rinsho; 2003 Sep 15; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract] [Full Text] [Related]

  • 57. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G, Lorico A, Sartorelli AC.
    Cancer Res; 1992 May 15; 52(10):2782-90. PubMed ID: 1316227
    [Abstract] [Full Text] [Related]

  • 58. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
    Bozko P, Larsen AK, Raymond E, Skladanowski A.
    Acta Biochim Pol; 2002 May 15; 49(1):109-19. PubMed ID: 12136930
    [Abstract] [Full Text] [Related]

  • 59. Induction of a common pathway of apoptosis by staurosporine.
    Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y.
    Exp Cell Res; 1994 Apr 15; 211(2):314-21. PubMed ID: 8143779
    [Abstract] [Full Text] [Related]

  • 60. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 15; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.